Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: WE89 who wrote (2945)	3/9/1999 10:36:00 PM
From: EZLibra	Read Replies (1) \| Respond to of 3702

Seems like the same company to me. Also sounds like the difference between European and American tolerance for life-threatening diseases. How long will we hear about the rubella mistake in the 50's versus the many successful european-trialed drugs since then? Is not Oncolym being trialed stateside anyway? The indication in the trial is for refractory NHL. When you have a terminal disease such as low, intermediate, or high grade NHL why not risk a small mortality incidence? BTW, there is a mortality risk with chemo in NHL but not so far with Oncolym. The first MoAB therapeutic approved for cancer in the U.S. belongs to Chiron. As I recall it is for renalstatic kidney cancer and in trials demonstrated a 5% CR rate and a 3% mortality rate.